SphK

Cat. No.

A65536

CAS No.

1449765-65-4

SLR080811

SLR080811 is a selective inhibitor of sphingosine kinase 2 (SphK2), with an inhibition constant (Ki) of 1.3 μM and approximately 10-fold selectivity over sphingosine kinase 1 (SphK1) with a Ki of 12 μM. This compound effectively reduces sphingosine 1-phosphate (S1P) levels in vitro, while also promoting a SphK1-dependent increase in S1P in in vivo mouse models. SLR080811 is suitable for research applications related to cancer and fibrosis, offering valuable insights into the role of sphingosine kinases in these disease processes.

Cat. No.

A65537

CAS No.

1382486-90-9

(R)-FTY720-OMe

(R)-FTY720-OMe is a selective inhibitor of sphingosine kinase 2 (SphK2), exhibiting an IC50 of 16.5 μM. This compound is valuable in research applications related to cancer, fibrosis, Alzheimer's disease, and sickle cell disease. Its ability to modulate sphingolipid metabolism makes it an important tool for studying these pathological conditions and their underlying mechanisms.

Cat. No.

A65538

CAS No.

1353880-00-8

VT-ME6

VT-ME6 is a selective inhibitor of sphingosine kinase 2 (SphK2), demonstrating a Ki value of 8 µM. This compound plays a pivotal role in the study of inflammatory diseases by modulating sphingolipid metabolism. Its specificity for SphK2 allows researchers to explore mechanisms underlying inflammation and related pathologies, making it a valuable tool for biochemical and pharmacological investigations.

Cat. No.

A65540

CAS No.

1185157-59-8

Opaganib hydrochloride

Synonyms: ABC294640 hydrochloride

Opaganib hydrochloride is a selective, competitive inhibitor of sphingosine kinase 2 (SK2) with a Ki of 9.8 μM. This compound is valuable in studying sphingosine metabolism and signaling pathways. Its biological activities make it a potential therapeutic agent in various cancer models and inflammatory diseases. Researchers can utilize Opaganib hydrochloride to investigate the role of SK2 in disease progression and to explore novel treatment strategies.